AC Camargo Cancer Center.2020 A. C. Camargo Cancer Center Departamento de Infectologia. Recomendações de vacinação para SARS CoV-2 em pacientes tratados no AC. Camargo Cancer Center [Internet]. 2021 [cited 2021 Feb 6]. Available from: https://accamargo.org.br/sites/default/files/2021/01/geral-recomendacoes-de-vacina-para_sars-cov-2-em-pacientes.pdf https://accamargo.org.br/sites/default/f...
|
When blood counts have recovered to the maximum (end of the cycle). Avoid the day of chemotherapy treatment. |
|
Cleared without restrictions. |
Cleared without restrictions, provided blood counts are normal. |
|
Cleared without restriction, provided blood counts are normal. |
|
|
Information obtained from Pfizer-BioNtech and AstraZeneca-Oxford vaccines |
National Comprehensive Cancer Network.2222 National Comprehensive Cancer Network. NCCN: cancer and COVID-19 vaccination: preliminary recommendations of the NCCN COVID-19 Vaccination Advisory Committee [Internet]. 2021 [cited 2021 Feb 6]. Available from: https://www.nccn.-org/docs/default-source/covid-19/2021_covid-19_vaccination_-guidance_v5-0.pdf https://www.nccn.-org/docs/default-sourc...
|
Cleared without restrictions. There is no evidence of optimal timing of vaccination during treatment. |
Cleared without restrictions |
Cleared without restrictions (not a priority when used exclusively by non-metastatic patients) |
Cleared without restrictions |
May reduce the immune response to vaccination. It is recommended to delay vaccination. |
Cleared without restrictions. |
Do not vaccinate on the day of the surgery because the vaccine symptoms. |
Yes. 1 b/c priority group by CDC. Patients under endocrine therapy are not prioritized. |
|
Memorial Sloan Kettering Cancer Center.2323 Kamboj MScope of the document In: Memorial Sloan Kettering Cancer Center. MSK COVID-19 vaccine interim guidelines for cancer patients [Internet]. 2021 [cited 2021 Feb 6]. p. 2-3. Available from: https://www.asco.org/sites/new-www.asco.-org/files/content-files/covid-19/2021-MSK-COVID19-VACCINE-GUIDELINES.pdf https://www.asco.org/sites/new-www.asco....
|
First dose between cycles, far apart from the nadir period, or after the end of the treatment if the latter is near completion. |
Cleared without restrictions |
Cleared without restrictions |
Cleared without restrictions |
Cleared without restrictions |
If possible, 2 weeks before the start of therapy |
Cleared without restrictions. Exceptions in cases of splenectomy |
Yes. Prioritize by age not according to location or presence of metastasis. |
Avoid immunotherapy or chemotherapy on 2nd or 3rd day after vaccination (period of increased risk vaccine side effects) |
European Society for Medical Oncology.2424 European Society for Medical Oncology. Summaries R. COVID-19 and patients with cancer. 2021;(January):1–48.
|
Cleared without restrictions. There is no evidence of the optimal timing of vaccination during treatment. |
|
|
|
|
Potential reduction in vaccine effectiveness. The benefits outweigh the risk. |
|
Yes, especially in patients with hematologic tumors (receiving chemotherapy or with active disease), advanced solid tumors, or history of solid tumor in the last 5 years. |
Protein kinase and PARP inhibitors do not have timing restrictions. Proteasome and CDK4/6 inhibitors should be used preferably at the end of the cycle, avoiding the day of chemotherapy treatment. |
Cancer Research UK.2525 Cancer Research UK. COVID-19 vaccine and cancer – latest updates [Internet]. 2020 [cited 2021 Jan 26]. Available from: https://scienceblog.cancerresearchuk.org/2020/12/15/covid-19-vaccine-and-cancer-latest-updates/ https://scienceblog.cancerresearchuk.org...
|
Optimal vaccination timing is before the start of the treatment. If treatment has already started, the patient should discuss the best timing for vaccination with the physician. |
Cleared without restrictions. |
|
|
|
Cleared without timing restrictions. Benefits are greater than costs. |
Vaccination is recommended 2 weeks before surgery. |
|
|
MD Anderson Cancer Center.2626 The University of Texas MD Anderson Cancer Center. COVID-19 vaccine information [Internet]. 2020 [cited2021 Jan 26]. Available from: https://www.mdanderson.org/patients-family/becoming-our-patient/planning-for-care/coronavirus-protections/covid-19-vaccine-information.html https://www.mdanderson.org/patients-fami...
|
Cleared. However, the optimal timing for vaccination should be discussed with the physician. |
|
|
|
|
Cleared. However, the optimal timing for vaccination should be discussed with the physician. |
Vaccination is recommended 2 weeks after surgery |
Yes. Increased COVID-19-related morbidity and mortality in cancer patients. |
|
Cancer Treatment Centers of America.2727 Cancer Treatment Centers of America. What cancer patients need to know about COVID-19 vaccines [Internet]. 2020 [cited 2021 Jan 26]. Available from: https://www.cancercenter.com/community/blog/2020/12/covid-vaccine-cancer-patients https://www.cancercenter.com/community/b...
|
Safe according to available data. Potential reduction in vaccine effectiveness during cancer treatment. A discussion with the physician is recommended. |
Safe according to available data. Potential reduction in vaccine effectiveness. |
|
|
|
|
|
|
Use of AstraZeneca Oxford vaccine is restricted in immunocompromised patients. |
Sociedade Brasileira de Oncologia Clínica.2828 Sociedade Brasileira de Oncologia Clínica. COVID-19: vacinação de pacientes oncológicos [Internet]. 2020 [cited 2021 Jan 26]. Available from: https://www.sboc.org.br/prevencao/item/2349-covid19-vacinacao-de-pacientes-oncologicos https://www.sboc.org.br/prevencao/item/2...
|
Cleared, but should be given preferably before the start of the treatment. |
|
|
|
Cleared. There is no evidence of the need for a second vaccine dose in immunosuppre-ssed patients. |
Cleared. Risk of interference with vaccine response and side effects. |
|
Yes. Increased Covid-19-related morbidity and mortality in cancer patients. |
|